Work

Therapy for chemopretreated metastatic urothelial cancer (mUC) with the antibody-drug conjugate (ADC) sacituzumab govitecan (IMMU-132).

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.6_suppl.327

Authors: Scott T. Tagawa, Allyson J. Ocean, Elaine Tat Lam, Philip James Saylor, Aditya Bardia, Julio Hajdenberg, Alicia Katherine Morgans, Kevin Kalinsky, Matthew Galsky, Bishoy Faltas, Ana M. Molina, Emerson A. Lim, Pius Maliakal, Robert M. Sharkey, Boyd Mudenda, William A. Wegener, David M Goldenberg

Institutions: Weill Cornell Medicine, University of Colorado Denver, Massachusetts General Hospital, Vanderbilt University Medical Center, Columbia University Irving Medical Center, Icahn School of Medicine at Mount Sinai, NewYork–Presbyterian Hospital, Immunomedics (United States)

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2598739848

Cites:

Cited by: 6

Related to: 10